- Home
- LGND vs BLTE Comparison
LGND vs BLTE Comparison
Compare LGND & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGND
- BLTE
- Stock Information
- Founded
- LGND 1987
- BLTE 2018
- Country
- LGND United States
- BLTE United States
- Employees
- LGND N/A
- BLTE N/A
- Industry
- LGND Biotechnology: Pharmaceutical Preparations
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- LGND Health Care
- BLTE Health Care
- Exchange
- LGND Nasdaq
- BLTE Nasdaq
- Market Cap
- LGND 2.0B
- BLTE 2.1B
- IPO Year
- LGND 1992
- BLTE 2022
- Fundamental
- Price
- LGND $122.40
- BLTE $64.16
- Analyst Decision
- LGND Strong Buy
- BLTE Strong Buy
- Analyst Count
- LGND 8
- BLTE 4
- Target Price
- LGND $144.71
- BLTE $96.67
- AVG Volume (30 Days)
- LGND 139.7K
- BLTE 51.9K
- Earning Date
- LGND 08-05-2025
- BLTE 08-08-2025
- Dividend Yield
- LGND N/A
- BLTE N/A
- EPS Growth
- LGND N/A
- BLTE N/A
- EPS
- LGND N/A
- BLTE N/A
- Revenue
- LGND $181,488,000.00
- BLTE N/A
- Revenue This Year
- LGND $18.41
- BLTE N/A
- Revenue Next Year
- LGND $18.87
- BLTE N/A
- P/E Ratio
- LGND N/A
- BLTE N/A
- Revenue Growth
- LGND 53.40
- BLTE N/A
- 52 Week Low
- LGND $81.74
- BLTE $43.70
- 52 Week High
- LGND $129.90
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- LGND 70.36
- BLTE 59.57
- Support Level
- LGND $111.72
- BLTE $56.10
- Resistance Level
- LGND $115.53
- BLTE $59.65
- Average True Range (ATR)
- LGND 3.46
- BLTE 2.45
- MACD
- LGND 0.18
- BLTE 0.36
- Stochastic Oscillator
- LGND 85.52
- BLTE 99.51
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.